Nektar Therapeutics (NKTR): EBITDA
-$139.08M
Year ended 2025-12-31
-$140.04M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$139.08M | n/m | 2026-03-13, From 2025-01-01 |
| 2024-12-31 | -$100.81M | n/m | 2026-03-13, From 2024-01-01 |
| 2023-12-31 | -$255.87M | n/m | 2025-03-14, From 2023-01-01 |
| 2022-12-31 | -$363.14M | n/m | 2024-03-05, From 2022-01-01 |
| 2021-12-31 | -$431.96M | n/m | 2024-03-05, From 2021-01-01 |
| 2020-12-31 | -$410.93M | n/m | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | -$426.88M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $698.80M | n/m | 2021-02-26, From 2018-01-01 |
| 2017-12-31 | -$44.90M | n/m | 2020-02-28, From 2017-01-01 |
| 2016-12-31 | -$97.50M | n/m | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | -$16.52M | n/m | 2018-03-01, From 2015-01-01 |
| 2014-12-31 | -$3.56M | n/m | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | -$105.86M | n/m | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | -$126.69M | n/m | 2015-02-26, From 2012-01-01 |
| 2011-12-31 | -$108.99M | n/m | 2014-02-27, From 2011-01-01 |
| 2010-12-31 | -$11.70M | n/m | 2013-03-01, From 2010-01-01 |
| 2009-12-31 | -$80.25M | n/a | 2012-02-29, From 2009-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Nektar Therapeutics (NKTR) | 2025-12-31 | -$139.08M | n/m |
| Integrated Biopharma Inc (INBP) | 2025-06-30 | $2.34M | +319.0% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | -$4.38M | n/m |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | -$265.69M | n/m |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | -$48.29M | n/m |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | -$211.32M | n/m |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | -$170.70M | n/m |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | -$80.76M | n/m |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | -$156.85M | n/m |
Compare NKTR, INBP, AYTU, OCUL side by side · Screen every company in Pharmaceutical Preparations ↗